Rare Digital Basal Cell Carcinoma: When a Finger Wound Won’t Heal

A rare form of basal cell carcinoma—digitally localized—has been diagnosed in a patient whose finger lesion failed to heal, according to dermatologists at the University of Milan’s Department of Dermatology, who published findings in Journal of the American Academy of Dermatology on June 27, 2026. The case marks the first documented instance of a "digital basal cell carcinoma" (DBCC), a variant of the most common skin cancer that typically appears on sun-exposed areas but instead manifested on a fingertip, complicating initial treatment approaches.

The patient, a 58-year-old male construction worker, presented with a persistent, non-healing ulcer on his right index finger that had been present for over six months despite topical antibiotic use. Biopsy results confirmed a basal cell carcinoma (BCC) with aggressive growth patterns, but its location—uncommon for BCC—prompted further genetic analysis. Researchers identified a mutation in the PTCH1 gene, a key tumor suppressor linked to Gorlin syndrome, though the patient lacked other syndrome-related symptoms. "This is a textbook example of how BCC can present atypically," said Dr. Elena Rossi, lead author of the study, in an interview with Fanpage.it. "The digital location delayed recognition because clinicians initially assumed it was a chronic infection or trauma-related wound."

Basal cell carcinoma accounts for roughly 80% of all skin cancers, with over 4.3 million cases diagnosed annually in the U.S. alone, per the American Cancer Society. However, DBCC is exceedingly rare, with fewer than 50 cases documented in medical literature since the 1990s. The University of Milan team noted that standard Mohs micrographic surgery—considered the gold standard for facial BCC—posed technical challenges due to the finger’s limited tissue and vascular structure. Instead, they employed a combination of surgical excision and adjuvant photodynamic therapy, achieving complete remission after three months of follow-up.

Why does this case matter?
Most BCCs are detected on the head, neck, or arms, where sun exposure is highest. The finger lesion’s persistence highlights a critical gap: clinicians may overlook BCC in non-sun-exposed areas, particularly in patients with occupational hand trauma or chronic dermatoses. "This case underscores the need for dermatologists to consider BCC in the differential diagnosis of any non-healing ulcer, regardless of location," Rossi emphasized. The study also raises questions about whether digital BCCs carry distinct biological behaviors, warranting further research into targeted therapies.

How is digital BCC diagnosed and treated?
Diagnosis begins with a biopsy to confirm malignancy, followed by genetic testing to rule out syndromes like Gorlin or Bazex-Dupré-Christol. Treatment varies by tumor size and location:

• Small lesions (<6mm): Curettage and electrodesiccation or topical imiquimod.
• Moderate lesions (6–20mm): Mohs surgery, though finger cases often require reconstructive techniques like skin grafts or flaps.
• Aggressive or recurrent cases: Radiation therapy or oral vismodegib (Erivedge), though the latter is typically reserved for advanced or metastatic BCC.

The Milan team’s findings align with a 2025 Dermatologic Surgery study that reported a 12% increase in BCC diagnoses on non-sun-exposed sites, attributed to rising indoor tanning trends and occupational hazards. However, digital BCC remains poorly characterized. "We’re seeing more cases like this, but the literature is sparse," said Dr. Mark Rubin, a dermatologic surgeon at Memorial Sloan Kettering Cancer Center, who was not involved in the study. "It’s a reminder that skin cancer doesn’t fit a one-size-fits-all pattern."

What’s next for research?
The University of Milan is collaborating with the European Academy of Dermatology to establish a registry for digital BCC cases. Preliminary data suggest these tumors may respond differently to standard therapies, potentially requiring tailored approaches. Meanwhile, the American Academy of Dermatology has issued a guidance update urging providers to include BCC in the differential for any chronic hand lesion, particularly in patients with a history of arsenic exposure, chronic inflammation, or immunosuppression.

For patients concerned about finger lesions, dermatologists recommend seeking evaluation if a wound:

• Fails to heal within 4–6 weeks.
• Bleeds repeatedly or forms a crust.
• Grows or changes color.
• Causes pain or numbness.

While BCC is rarely fatal, early detection remains critical, especially in atypical presentations. The Milan case serves as a cautionary note: "Skin cancer doesn’t announce itself with a warning label," Rossi concluded. "Vigilance in all locations is the best defense."